Genotoxic activity of newly synthesized imidazolyl derivatives in mouse lymphoma and bone marrow cells

Experimental Oncology

Volumn 25, Issue 4, 2003, Pages 266-269

  Nersesyan, A K ^a   Melikyan, G S ^b   Muradyan, R E ^c   Stopper, H ^d  

^a Cancer Research Institute   (Armenia)

^b YEREVAN STATE UNIVERSITY   (Armenia)

^c Institute of Fine Organic Chemistry   (Armenia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Comet assay; Imidazolyl derivatives; L5178Y mouse lymphoma cells; Micronuclei; Mouse bone marrow cells

Indexed keywords

3 (1 IMIDAZOLYL)PROPYL 4 METHYL 1 OXASPIRO[4.5]DECA 3 EN 2 ONE; 3 (1 IMIDAZOLYL)PROPYLAMIDE 4,5,5 TRIMETHYL DELTA3 BUTENOLIDE; 3 (1 IMIDAZOLYL)PROPYLAMIDE 4,5,5 TRIMETHYLPYRROLIN 2 ONE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; IMIDAZOLE DERIVATIVE; LACTAME; LACTONE DERIVATIVE; MITOMYCIN C; UNCLASSIFIED DRUG; 3 (IMIDAZOLYL 1) PROPYLAMIDE 4,5,5 TRIMETHYL DELTA 3 BUTENOLID; [3 (IMIDAZOLYL 1) PROPYL 4 METHYL 1 OXASPIRO (4,5) DECA 3 EN 2 ONE]; [3 (IMIDAZOLYL 1) PROPYLAMIDE 4,5,5 TRIMETHYL PYRROLIN 2 ONE;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL CULTURE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; GENOTOXICITY; LD 50; LYMPHOMA CELL; MALE; MICRONUCLEUS; MOUSE; MUTAGENICITY; NONHUMAN; TOXICITY TESTING; ANIMAL EXPERIMENT; ERYTHROCYTE; HEMATOPOIETIC CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA;

EID: 0842308167     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Leite L, Jansone D, Shestakova I, Domracheva I, Veretennikova N, Lukevics E, Melikyan G. Synthesis and antitumor effect of aryl (heteryl) γ- and δ-lactones. Drugs of the Future 2002; 27: 336.
2. Veretennikova N, Skorova A, Jansone D, Lukevics E, Leite L, Melikyan G. Synthesis and computer prediction of the pharmacological activity of aryl γ- and δ-lactams. Drugs of the Future 2002; 27: 482.
3. Dearfield KL, Cimino MC, McCarroll NE, Mauer I, Valgovic LR. Genotoxicity risk assessment: a proposed classification strategy. Mutat Res 2002; 521: 121-35.
4. Boos G, Stopper H. Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 2000; 116: 7-16.
5. Moller M, Adam W, Saha-Moller CR, Stopper H. Studies on cytotoxic and genotoxic effects of N-hydroxy-pyridine-2-thione (Omadine) in L5178Y mouse lymphoma cells. Toxicol Lett 2002; 136: 77-84.
6. Singh NT, McCoy MT, Tice RR, Schneider EL. A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-91.
7. Melikyan G, Ronessac F, Alexandre C. A convenient synthesis of substituted 3-pyrrolin-2-ones from cetols. Synth Commun 1993; 23: 2631-3.
8. Nersesyan AK, Melikyan GS, Stopper H. The study of genotoxicity of two newly synthesized pyrrolinone derivatives on mouse lymphoma and bone marrow cells. Exp Oncol 2003; 25: 176-9.
9. Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol 1983; 54: 275-87.
10. Yegorov LV, Rechnikov VP, Fertukova NM, Ivanova LE, Kuznetsova TV. The prescreening of antitumor drugs. Exp Oncol 1991; 13: 74-7 (In Russian).
11. Kirkhart B. Micronucleus test on 21 compounds. In: Evaluation of short-term tests for carcinogens. Ashby J, de Serres FJ, Shelby MD, Margolin BH, Ishidate M, Beckong GG, eds. Geneva: University Press, 1981; 1: 698-704.
12. Glaxo Smith Kline. Oncology Prescribing Guide. Montvale, NJ, USA, 2001: Medical Economics Company, Inc.
13. WHO/IARC. IARC Monographs on the evaluation of the carcinogenic risks to humans. Genetic and related effects: an updating of selected IARC monographs from volumes 1-42. IARC Monographs, Supplement 6, 1987: Lyon, France.
14. Nersesyan AK. Anthrax live vaccine as modifier of mutagenesis and carcinogenesis. In: Confronting infections, antibiotic resistance, and bioterrorism around the world. de The G, Challoner D, Auquier L, eds. InterAcademy Medical Panel: Elsevier, 2002; 131-6.